Phase II study of oral APL-1202 plus tislelizumab or tislelizumab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC).

Vesique (nitroxoline) - Asieris

Tevimbra (tislelizumab-jsgr) - BeOne Medicines

Matthew Galsky; John Sfakianos; Dingwei Ye; Badrinath Konety; Dalin He; Xiaodong Song; Hailong Hu; Hanzhong Li; Gongxian Wang; Xiaoliang Yuan

Jan 7, 2025